ECSP13012481A - Composiciones de anticuerpo anti-vegfr-3 - Google Patents
Composiciones de anticuerpo anti-vegfr-3Info
- Publication number
- ECSP13012481A ECSP13012481A ECSP13012481A ECSP13012481A EC SP13012481 A ECSP13012481 A EC SP13012481A EC SP13012481 A ECSP13012481 A EC SP13012481A EC SP13012481 A ECSP13012481 A EC SP13012481A
- Authority
- EC
- Ecuador
- Prior art keywords
- vegfr
- antibody compositions
- antibodies
- diseases
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38043210P | 2010-09-07 | 2010-09-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13012481A true ECSP13012481A (es) | 2015-03-31 |
Family
ID=44584686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13012481 ECSP13012481A (es) | 2010-09-07 | 2013-03-06 | Composiciones de anticuerpo anti-vegfr-3 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8481034B2 (enExample) |
| EP (1) | EP2614081B1 (enExample) |
| JP (1) | JP2013538813A (enExample) |
| KR (1) | KR20130042601A (enExample) |
| CN (1) | CN103080133A (enExample) |
| AR (1) | AR082641A1 (enExample) |
| AU (1) | AU2011299443B2 (enExample) |
| BR (1) | BR112013005423A2 (enExample) |
| CA (1) | CA2809375C (enExample) |
| CL (1) | CL2013000607A1 (enExample) |
| CO (1) | CO6690754A2 (enExample) |
| CR (1) | CR20130065A (enExample) |
| DO (1) | DOP2013000039A (enExample) |
| EA (1) | EA023331B1 (enExample) |
| EC (1) | ECSP13012481A (enExample) |
| ES (1) | ES2568801T3 (enExample) |
| GT (1) | GT201300058A (enExample) |
| MA (1) | MA34487B1 (enExample) |
| MX (1) | MX2013002718A (enExample) |
| PE (1) | PE20131328A1 (enExample) |
| PH (1) | PH12013500432A1 (enExample) |
| SG (1) | SG188265A1 (enExample) |
| TW (1) | TWI413527B (enExample) |
| UA (1) | UA109148C2 (enExample) |
| WO (1) | WO2012033696A1 (enExample) |
| ZA (1) | ZA201300804B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014064203A1 (en) | 2012-10-26 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis |
| KR101521981B1 (ko) * | 2013-07-31 | 2015-05-20 | 가톨릭대학교 산학협력단 | 혈액암 줄기세포 증식 또는 생착 억제용 조성물 |
| EP3244924B1 (en) * | 2015-01-15 | 2021-04-07 | Oncoquest Pharmaceuticals Inc. | Methods of increasing delivery of anti-cancer agents to targets |
| CA3044682A1 (en) | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| CN110004167A (zh) * | 2019-04-16 | 2019-07-12 | 中国医学科学院血液病医院（血液学研究所） | 靶向vegfr-2和/或vegfr-3嵌合抗原受体及其应用 |
| CN111808191A (zh) * | 2020-05-11 | 2020-10-23 | 廊坊天光生物技术有限公司 | 一种用于检测血清中vegf含量的抗体对及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002248372B8 (en) * | 2001-01-19 | 2008-03-20 | Vegenics Limited | FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| CN101277976B (zh) | 2005-10-06 | 2012-04-11 | 伊莱利利公司 | 抗肌抑制素抗体 |
-
2011
- 2011-08-25 AR ARP110103100A patent/AR082641A1/es unknown
- 2011-08-26 TW TW100130812A patent/TWI413527B/zh not_active IP Right Cessation
- 2011-09-01 US US13/223,344 patent/US8481034B2/en active Active
- 2011-09-01 EA EA201390117A patent/EA023331B1/ru not_active IP Right Cessation
- 2011-09-01 JP JP2013527303A patent/JP2013538813A/ja active Pending
- 2011-09-01 CN CN2011800430574A patent/CN103080133A/zh active Pending
- 2011-09-01 EP EP11754805.7A patent/EP2614081B1/en active Active
- 2011-09-01 SG SG2013013107A patent/SG188265A1/en unknown
- 2011-09-01 ES ES11754805.7T patent/ES2568801T3/es active Active
- 2011-09-01 CA CA2809375A patent/CA2809375C/en not_active Expired - Fee Related
- 2011-09-01 MA MA35695A patent/MA34487B1/fr unknown
- 2011-09-01 KR KR1020137005794A patent/KR20130042601A/ko not_active Ceased
- 2011-09-01 BR BR112013005423A patent/BR112013005423A2/pt not_active IP Right Cessation
- 2011-09-01 UA UAA201302462A patent/UA109148C2/uk unknown
- 2011-09-01 WO PCT/US2011/050131 patent/WO2012033696A1/en not_active Ceased
- 2011-09-01 AU AU2011299443A patent/AU2011299443B2/en not_active Ceased
- 2011-09-01 PE PE2013000380A patent/PE20131328A1/es not_active Application Discontinuation
- 2011-09-01 MX MX2013002718A patent/MX2013002718A/es unknown
- 2011-09-01 PH PH1/2013/500432A patent/PH12013500432A1/en unknown
-
2013
- 2013-01-30 ZA ZA2013/00804A patent/ZA201300804B/en unknown
- 2013-02-14 DO DO2013000039A patent/DOP2013000039A/es unknown
- 2013-02-15 CR CR20130065A patent/CR20130065A/es unknown
- 2013-03-04 CL CL2013000607A patent/CL2013000607A1/es unknown
- 2013-03-05 GT GT201300058A patent/GT201300058A/es unknown
- 2013-03-06 EC ECSP13012481 patent/ECSP13012481A/es unknown
- 2013-03-07 CO CO13046124A patent/CO6690754A2/es unknown
- 2013-05-07 US US13/888,716 patent/US8784818B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EA023331B1 (ru) | 2016-05-31 |
| CN103080133A (zh) | 2013-05-01 |
| ZA201300804B (en) | 2014-07-30 |
| DOP2013000039A (es) | 2013-04-15 |
| CO6690754A2 (es) | 2013-06-17 |
| AU2011299443A1 (en) | 2013-02-14 |
| PE20131328A1 (es) | 2013-11-18 |
| TWI413527B (zh) | 2013-11-01 |
| US8784818B2 (en) | 2014-07-22 |
| SG188265A1 (en) | 2013-04-30 |
| EA201390117A1 (ru) | 2013-06-28 |
| TW201223543A (en) | 2012-06-16 |
| MA34487B1 (fr) | 2013-08-01 |
| US8481034B2 (en) | 2013-07-09 |
| KR20130042601A (ko) | 2013-04-26 |
| CR20130065A (es) | 2013-03-21 |
| BR112013005423A2 (pt) | 2016-06-07 |
| CA2809375A1 (en) | 2012-03-15 |
| EP2614081B1 (en) | 2016-03-16 |
| WO2012033696A1 (en) | 2012-03-15 |
| GT201300058A (es) | 2014-07-16 |
| CA2809375C (en) | 2016-02-09 |
| AR082641A1 (es) | 2012-12-19 |
| US20130280278A1 (en) | 2013-10-24 |
| US20120058126A1 (en) | 2012-03-08 |
| UA109148C2 (uk) | 2015-07-27 |
| AU2011299443B2 (en) | 2014-06-05 |
| PH12013500432A1 (en) | 2017-08-23 |
| EP2614081A1 (en) | 2013-07-17 |
| MX2013002718A (es) | 2013-05-01 |
| CL2013000607A1 (es) | 2014-04-11 |
| JP2013538813A (ja) | 2013-10-17 |
| ES2568801T3 (es) | 2016-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20120215A (es) | Anticuerpos contra csf-1r humano y usos de los mismos | |
| GT201300306A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| CY1120413T1 (el) | Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου | |
| CY1120398T1 (el) | Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη | |
| MX2014009289A (es) | Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer. | |
| CY1119852T1 (el) | Σκευασμα αντισωματος και θεραπευτικα σχηματα | |
| ECSP12011701A (es) | Anticuerpos anti-cdcp1 humanizados | |
| BR112013028908A2 (pt) | anticorpos c-kit e usos dos mesmos | |
| MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
| MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| CO6551674A2 (es) | Anticuerpos anti-her3 y usos de los mismo | |
| CR20110466A (es) | Anticuerpos biespecíficos anti-erbb-3/anti-c-met | |
| MX2016008098A (es) | Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso. | |
| EA201401204A1 (ru) | Антитела к il-23p19 | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| BR112013027500A2 (pt) | liberação controlada de imunossupressores de nanotransportadores sintéticos | |
| MX373245B (es) | Anticuerpos cd3 humanizados o quiméricos. | |
| CL2014001345A1 (es) | Metodos de tratamiento usando un anticuerpo contra interferon gamma; usos composicion farmaceutica que contiene un anticuerpo contra interferon gamma. | |
| MA32712B1 (fr) | Anticorps anti-vegf/anti-ang-2 bispecifique | |
| ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| MX382840B (es) | Regiones de anticuerpo modificado y sus usos. | |
| ECSP088778A (es) | Formulacion de un anticuerpo monoclonal humano anti-igf-1r | |
| EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения |